TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+11.93%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.58B
AUM Growth
+$2.58B
(+9.9%)
Cap. Flow
+$15.1M
Cap. Flow
% of AUM
0.59%
Top 10 Holdings %
Top 10 Hldgs %
43.75%
Holding
150
New
7
Increased
20
Reduced
25
Closed
10
Top Buys
| 1 |
Amgen
AMGN
|
$59.6M |
| 2 |
Johnson & Johnson
JNJ
|
$33.8M |
| 3 |
Viatris
VTRS
|
$16.2M |
| 4 |
McKesson
MCK
|
$14.5M |
| 5 |
Thermo Fisher Scientific
TMO
|
$13.3M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$29.5M |
| 2 |
MDCO
Medicines Co
MDCO
|
$26.2M |
| 3 |
Incyte
INCY
|
$25M |
| 4 |
Abbott
ABT
|
$19.1M |
| 5 |
Centene
CNC
|
$18.2M |
Sector Composition
| 1 | Healthcare | 91.08% |
| 2 | Real Estate | 3.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $172M | 6.66% |
2,530,131
| – | – |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $170M | 6.59% |
1,366,605
-43,284
| -3% | -$5.39M |
|
3
Biogen
BIIB
$20.5B
| $133M | 5.14% |
484,974
-52,376
| -10% | -$14.3M |
|
4
Vertex Pharmaceuticals
VRTX
$103B
| $113M | 4.38% |
1,033,503
| – | – |
|
|
5
Amgen
AMGN
$154B
| $112M | 4.36% |
684,824
+363,184
| +113% | +$59.6M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $96.5M | 3.74% |
795,905
| – | – |
|
|
7
Incyte
INCY
$16.8B
| $92.7M | 3.59% |
693,275
-187,186
| -21% | -$25M |
|
|
8
Johnson & Johnson
JNJ
$429B
| $89M | 3.45% |
714,362
+271,150
| +61% | +$33.8M |
|
9
Merck
MRK
$214B
| $76.1M | 2.95% |
1,198,349
| – | – |
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $74.2M | 2.88% |
310,610
-123,476
| -28% | -$29.5M |
|
11
Regeneron Pharmaceuticals
REGN
$61.3B
| $72.7M | 2.82% |
187,666
| – | – |
|
|
12
Viatris
VTRS
$12.3B
| $60.5M | 2.34% |
1,550,412
+414,860
| +37% | +$16.2M |
|
|
13
Abbott
ABT
$229B
| $51.2M | 1.98% |
1,152,520
-431,180
| -27% | -$19.1M |
|
14
Illumina
ILMN
$15.5B
| $50.7M | 1.97% |
297,360
+50,800
| +21% | +$8.67M |
|
15
UnitedHealth
UNH
$280B
| $50.3M | 1.95% |
306,852
+60,932
| +25% | +$9.99M |
|
16
Medtronic
MDT
$120B
| $49.4M | 1.91% |
613,030
-10,000
| -2% | -$806K |
|
17
Jazz Pharmaceuticals
JAZZ
$7.87B
| $48.1M | 1.86% |
331,411
| – | – |
|
18
BioMarin Pharmaceuticals
BMRN
$11.3B
| $44.4M | 1.72% |
505,845
-66,800
| -12% | -$5.86M |
|
19
Eli Lilly
LLY
$659B
| $41.5M | 1.61% |
493,100
| – | – |
|
|
SHPG
20
DELISTED
Shire pic
SHPG
| $40.3M | 1.56% |
231,413
| – | – |
|
21
Pfizer
PFE
$142B
| $39.2M | 1.52% |
1,146,689
| – | – |
|
|
22
Thermo Fisher Scientific
TMO
$184B
| $35M | 1.36% |
228,020
+86,900
| +62% | +$13.3M |
|
23
Teva Pharmaceuticals
TEVA
$21.5B
| $32.6M | 1.26% |
1,015,758
+226,800
| +29% | +$7.28M |
|
24
CVS Health
CVS
$94B
| $32.3M | 1.25% |
411,891
| – | – |
|
25
Humana
HUM
$37.3B
| $31.7M | 1.23% |
153,800
-11,000
| -7% | -$2.27M |
|